CFC-Only Asthma Drugs Likely To Lose “Essential Use” Designation
Executive Summary
FDA is likely to initiate proceedings to revoke the "essential use" designation for remaining chlorofluorocarbon-propelled asthma drug products following a lack of strong support by FDA's Pulmonary-Allergy Drugs Advisory Committee for continued use of any of the productsYou may also be interested in...
FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds
FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds
Kos Azmacort HFA Submission In ’07 Could Lead To Removal Of CFC Version
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: